Health Care • Biotechnology: Pharmaceutical Preparations
$1.08 ▼ -0.04
(-3.57%)
MKT CAP: $58.2M • VOL: 67.2K
52W L $1 52W H $4
RFL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-07-31 | FY 2024
FILED 2024-07-31 | FY 2023
FILED 2023-07-31 |
|---|---|---|---|
| Revenue (Total Sales) | $30.0K | $637.0K | $279.0K |
| YoY Revenue Growth % | -95.3% | +128.3% | — |
| Gross Profit | — | $483.0K | — |
| Gross Margin % | — | 75.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$29.2M | -$102.6M | -$15.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$30.5M | -$34.4M | -$1.9M |
| EBITDA (Normalized) | -$29.2M | -$102.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.9M | -$7.8M | -$10.9M |
| Capital Expenditures (CapEx) | $4.0K | $143.0K | — |
| Free Cash Flow (FCF) | -$18.9M | -$7.9M | -$10.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $37.8M | $48.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $79.2M | $69.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RFL.